RBMX and T-cell non-Hodgkin lymphoma: In conclusion, our study found that low RBMX protein expression predicted better response to anthracycline-containing first-line treatment, overall survival, and progression-free survival in patients with T-cell non-Hodgkin’s lymphomas.